Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leen Timbermont

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
The Lancet. Infectious Diseases|April 24, 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Hasan S Jafri, Jean Chastre, et al.
Critical Care (London, England)|November 15, 2022
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Bruno François, Marc Bourgeois, et al.
JAMA Network Open|October 31, 2023
Postoperative Staphylococcus aureus Infections in Patients With and Without Preoperative ColonizationDarren P R Troeman, Derek Hazard, Leen Timbermont, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
The Lancet. Infectious Diseases|April 24, 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Hasan S Jafri, Jean Chastre, et al.
Critical Care (London, England)|November 15, 2022
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Bruno François, Marc Bourgeois, et al.
JAMA Network Open|October 31, 2023
Postoperative Staphylococcus aureus Infections in Patients With and Without Preoperative ColonizationDarren P R Troeman, Derek Hazard, Leen Timbermont, et al.
Pageof 4